This website is fully funded and supported by Gilead Sciences Ltd

Gilead is dedicated to supporting communities with life‑threatening diseases

In December 2019, a novel virus causing flu-like symptoms emerged in Wuhan, Hubei Province, China. Within three months, the World Health Organization declared the spread of the coronavirus-19 (COVID-19) to be a global pandemic.1 Since then, COVID-19 has drastically changed the world in which we live.

For more information on symptoms, testing, vaccination and self-isolation, please click here.

At Gilead we remain committed to pursuing the impossible, working tirelessly to bring forward medicines for life-threatening diseases. If you are a member of the public and would like to access the patient information on Gilead COVID-19 medicines, click here.

REFERENCES AND FOOTNOTES

COVID-19, coronavirus disease 2019.

  1. World Health Organisation. WHO Director-General opening remark at the media briefing on COVID-19 – 11 March 2020.
    Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. Accessed September 2021.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse Event Reporting
Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or via the Yellow Card app (download from the Apple App Store or Google Play Store). For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to Safety_FC@gilead.com or +44 (0) 1223 897500.

Date of preparation: 09/21 Section job code: UK-VKY-0043

DISCLAIMER: This link will take you to an external, third-party website. Gilead is not responsible for and does not control the content of this third-party website